Cargando…

Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?

BACKGROUND: The underlying disease mechanism of neuropsychiatric symptoms (NPS) in dementia remains unclear. Cerebrospinal fluid (CSF) biomarkers for synaptic and axonal degeneration may provide novel neuropathological information for their occurrence. The aim was to investigate the relationship bet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bloniecki, Victor, Zetterberg, Henrik, Aarsland, Dag, Vannini, Patrizia, Kvartsberg, Hlin, Winblad, Bengt, Blennow, Kaj, Freund-Levi, Yvonne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670701/ https://www.ncbi.nlm.nih.gov/pubmed/33203439 http://dx.doi.org/10.1186/s13195-020-00718-y

Ejemplares similares

Agitation in Dementia: Relation to Core Cerebrospinal Fluid Biomarker Levels
por: Bloniecki, Victor, et al.
Publicado: (2014)

Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2020)

Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease
por: Hellwig, Konstantin, et al.
Publicado: (2015)

Cerebrospinal fluid biomarkers of axonal and synaptic degeneration in a population-based sample
por: Arvidsson Rådestig, Maya, et al.
Publicado: (2023)

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
por: Cicognola, Claudia, et al.
Publicado: (2021)

Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers
por: Camporesi, Elena, et al.
Publicado: (2021)

The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
por: Kvartsberg, Hlin, et al.
Publicado: (2018)

Molecular forms of neurogranin in cerebrospinal fluid
por: Nazir, Faisal Hayat, et al.
Publicado: (2020)

Analytical and clinical validation of a blood progranulin ELISA in frontotemporal dementias
por: Meda, Francisco, et al.
Publicado: (2023)

Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
por: Bergman, Joakim, et al.
Publicado: (2016)

γ‐Secretase modulators show selectivity for γ‐secretase–mediated amyloid precursor protein intramembrane processing
por: Weber, Tobias A., et al.
Publicado: (2021)

Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer’s Disease
por: Smailovic, Una, et al.
Publicado: (2021)

Phenotypic Screening Identifies Modulators of Amyloid Precursor Protein Processing in Human Stem Cell Models of Alzheimer’s Disease
por: Brownjohn, Philip W., et al.
Publicado: (2017)

CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study
por: Milà-Alomà, Marta, et al.
Publicado: (2021)

Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias
por: Hanes, Jozef, et al.
Publicado: (2020)

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
por: Duits, Flora H., et al.
Publicado: (2018)

Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays
por: Öhrfelt, Annika, et al.
Publicado: (2020)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

Synaptic proteins in CSF relate to Parkinson’s disease stage markers
por: Bereczki, Erika, et al.
Publicado: (2017)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase
por: Becker, Bruno, et al.
Publicado: (2018)

CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
por: Simrén, Joel, et al.
Publicado: (2022)

Impaired synaptic function is linked to cognition in Parkinson's disease
por: Selnes, Per, et al.
Publicado: (2017)

Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry
por: Camporesi, Elena, et al.
Publicado: (2022)

CSF synaptic protein concentrations are raised in those with atypical Alzheimer’s disease but not frontotemporal dementia
por: Clarke, Mica T. M., et al.
Publicado: (2019)

Psychiatric and neuropsychiatric syndromes and COVID-19
por: Velayudhan, Latha, et al.
Publicado: (2020)

Neurological Assessment and Its Relationship to CSF Biomarkers in Amateur Boxers
por: Neselius, Sanna, et al.
Publicado: (2014)

Increased CSF Levels of Phosphorylated Neurofilament Heavy Protein following Bout in Amateur Boxers
por: Neselius, Sanna, et al.
Publicado: (2013)

Repeated lumbar punctures within 3 days may affect CSF biomarker levels
por: Olsson, Martin, et al.
Publicado: (2019)

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
por: Skillbäck, Tobias, et al.
Publicado: (2013)

Extracellular fluid, cerebrospinal fluid and plasma biomarkers of axonal and neuronal injury following intracerebral hemorrhage
por: Tobieson, Lovisa, et al.
Publicado: (2021)

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
por: Kvartsberg, Hlin, et al.
Publicado: (2015)

CSF-Biomarkers in Olympic Boxing: Diagnosis and Effects of Repetitive Head Trauma
por: Neselius, Sanna, et al.
Publicado: (2012)

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
por: Henjum, Kristi, et al.
Publicado: (2018)

Neuroinflammation and Alzheimer’s Disease: A Machine Learning Approach to CSF Proteomics
por: Gaetani, Lorenzo, et al.
Publicado: (2021)

Neurofilament light oligomers in neurodegenerative diseases: quantification by homogeneous immunoassay in cerebrospinal fluid
por: Meda, Francisco J., et al.
Publicado: (2023)

Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease
por: Buchhave, Peder, et al.
Publicado: (2009)

The importance of co-pathologies on neuropsychiatric symptoms in dementia
por: Gibson, Lucy L., et al.
Publicado: (2022)

Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression
por: Siafarikas, Nikias, et al.
Publicado: (2021)

No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
por: Cicognola, Claudia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fce3ef6d31h2mjgr8o42r780f3